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Abstract A significant proportion of ovarian malignancies
consists of metastatic tumors, with a wide variety in site of
origin. Differentiating between a primary and metastatic ma-
lignancy of the ovaries can be difficult and misdiagnosis
might have considerable impact on both treatment and prog-
nosis. To further examine the origin of malignancies metasta-
tic to the ovary, we performed a large-scale, nationwide search
for ovarian metastases in the Dutch Pathology Registry
(PALGA). All pathology reports concerning malignancies
metastatic to the ovary and associated primary tumors in the
Netherlands between 2000 and 2010 were collected. Age,
year of diagnosis, tumor type, location of the primary tumor,
and side of the ovarian tumor were extracted from the data-
base. We identified 2312 patients fulfilling our selection
criteria. The most common primary malignancy sites were
colon (33.2 %), endometrium (17.1 %), breast (14.3 %), ap-
pendix (7.3 %), and stomach (4.5 %). The metastases were
most frequently bilateral (46.3 %) followed by unilateral me-
tastases in the right (26.7 %) and left ovary (19.8 %), while
side was unknown in 7.2 % of cases. Of colorectal carcino-
mas, only 40.2 % metastasized bilaterally, compared to
63.9 % of breast, 62.9 % of gastric, and 58.9 % of appendix
carcinomas. Left-sided colorectal carcinomas most often me-
tastasized to the left ovary (p<0.0001). We found colon car-
cinomas to be most frequently responsible for metastases to
the ovaries, followed by endometrial and breast carcinomas.
Metastases from breast, stomach, and appendix carcinomas
were mostly bilateral, whereas metastases from colorectal car-
cinomas were mostly unilateral. The mechanisms underlying
preferred sites for metastasis or side remain unclear.
Keywords Ovarian cancer . Mucinous ovarian carcinoma .
Metastasis . Epidemiology
Introduction
Malignancies metastatic to the ovary are estimated to account
for 5–30 % of all ovarian malignancies [1–8]. These most
commonly originate from the colorectum, followed by endo-
metrium, stomach, appendix, and breast [1, 2, 6–9]. Differen-
tiating between a primary and metastatic malignancy of the
ovaries can be complex as many metastatic carcinomas mimic
primary ovarian carcinomas [9]. Mucinous ovarian carcino-
mas (MOC) are notoriously difficult to distinguish from met-
astatic adenocarcinomas, and as a consequence, the latter are
often misdiagnosed as primary tumors [10–13]. A small study
[11] claimed that as many as 40 out of the 52MOC turned out
to be metastases. However, the exact incidence of metastatic
disease within the group of MOC is hard to determine. Algo-
rithms as suggested in previous studies [8, 11] are not suffi-
cient to identify all carcinomas metastatic to the ovary. Over-
lapping marker patterns between gynecological and gastroin-
testinal malignancies limit the usefulness of immunohisto-
chemistry [9].
Since the treatment of choice of primary ovarian malignan-
cies is different from that of metastatic disease to the ovary,
misdiagnoses may have important consequences. As survival
data are mostly based upon series containing a mixture of
metastatic carcinomas and MOC, these are most likely biased.
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Although several studies focused on malignancies metastatic
to the ovary, most were based upon small patient populations.
Therefore, which malignancies most often metastasize to the
ovary and which underlying pathways might be involved re-
mains largely unclear. The purpose of the present large-scale,
nationwide study was to gain more insight in primary tumor
sites.
Materials and methods
Study population
The nationwide network and registry of histo- and cytopathol-
ogy in the Netherlands (PALGA) codes and saves pathology
reports in the Netherlands as of 1971 with nationwide cover-
age as of 1991 [14]. The search terms “ovary” and “all metas-
tases” were used for the years 2000–2010 to collect all
pathology reports concerning malignancies metastatic to
the ovary. Conclusions of reports were used for further
data analysis. A flow chart of the exclusion process is depicted
in Fig. 1.
For each patient, the following items were collected from
the pathology report: age at time of diagnosis of ovarian
metastasis, year of histological diagnosis, histological type
and location of the primary malignancy, and side of the in-
volved ovary. Survival data were not accessible.
Only metastases of which the primary site had been histo-
logically verified were included, and these were classified per
organ. Primary squamous or basal cell carcinomas of the skin
were excluded. Cases with diagnoses based upon cytology
only were excluded from the study. When a carcinoma was
clearly not an ovarian primary but histological evidence iden-
tifying the primary site was lacking, it was classified as “pri-
mary site unknown.” Malignancies of which the distinction
between primary and metastatic could not be made with cer-
tainty were labeled as “indeterminate site.” For endometrioid
carcinomas, several histological criteria have been proposed
to distinguish two synchronous primaries from one tumor be-
ing a metastasis from the other, although it is generally accept-
ed that these are not always conclusive and definitive distinc-
tion is often not possible [15]. Primary fallopian tube
carcinomas were excluded since new insight suggests
that these are at least partly precursors of ovarian neo-
plasms [16]. Carcinomas in the ovary were classified by
histological type. Metastatic carcinomas of gastrointesti-
nal tract origin were classified as mucinous carcinoma,
unless the pathology report stipulated a different specific
histological type. When signet-ring cells were present,
the carcinoma was classified as signet-ring cell carcino-
ma. Carcinomas with more than one histological sub-
type were classified as mixed. If a colorectal carcinoma
was reported to invade the ovary directly, it was exclud-
ed since these are considered T4 rather than M1 carci-
nomas according to the latest TNM classification. Peri-
toneal lesions composed of abundant extracellular mu-
cin, containing scant simple to focally proliferative mu-
cinous epithelium with little cytologic atypia or mitotic
activity, were considered as disseminated peritoneal
adenomucinosis (DPAM). Peritoneal lesions composed
of more abundant mucinous epithelium with the archi-
tectural and cytologic features of carcinoma were con-
sidered as peritoneal mucinous carcinomatosis (PMCA).
Not all reports mentioned specific criteria or immuno-
histochemical staining used to reach a final diagnosis.
The data used was anonymous. The scientific committee
of PALGA approved this study.
Statistical analysis
All analyses were performed using SPSS (Statistical Package
for the social science; SPSS Inc, Chicago, Illinois) version
20.0. The chi-square test was used to compare multiple nom-
inal variables. Distribution of median age was compared using
a Mann-WhitneyU test, and the sign test was used to compare
two nominal variables. A p value≤0.05 was considered statis-
tically significant.Fig. 1 Flow chart of exclusion process
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Results
Patient characteristics
Our search identified 19,403 pathology reports concerning
9980 patients, of which we included 2312 patients (Fig. 1).
Median age of all patients with a malignancy metastatic to the
ovary was 59 years (range 15–95). Median age of patients
with a primary carcinoma of breast (49.5, p<0.0001), lung
(46, p<0.0001), stomach (55, p=0.002), and skin (46.5, p=
0.018) was significantly lower and that of patients with a
primary carcinoma of bladder (67, p=0.021) or endometrium
(64, p<0.0001) significantly higher compared to that of pa-
tients with a primary carcinoma from other sites. Further de-
tails are listed in Table 1.
Primary tumor sites
Of the 2312 malignancies metastatic to the ovary, the primary
tumor was histologically confirmed in 1930 (83.4 %) cases.
The most common primary site was colorectum (n=767,
33.2 %), followed by endometrium (n=395, 17.1 %), breast
(n=330, 14.3 %), appendix (n=169, 7.3 %), and stomach (n=
103, 4.5 %), as depicted in Fig. 2.
In 348 cases (15.1 %), the primary site was unknown, but
in 261 (75.0 %) of these, a primary location was suggested in
the pathology report. Colorectum (n=65, 18.7 %) was the
most commonly suggested primary site, followed by stomach
(n=33, 9.5 %), upper gastrointestinal tract (gallbladder, pan-
creas or stomach) (n=37, 10.7 %), breast (n=26, 7.5 %), ap-
pendix (n=25, 7.2 %) or other (n=14, 4.1 %). Gastrointestinal
tract without any specification of the location was suggested
in 61 cases (17.5 %). In 87 cases (25.0 %), no primary site was
suggested.
In 34 cases (1.5 %), the primary site was indeterminate.
The remaining malignancies metastatic to the ovary (7.0 %)
originated from rare primary sites. Further details on primary
sites are listed in Table 1.
Histopathology
Mucinous carcinoma was the most common histological type
(n=1082, 46.7%), followed by signet-ring cell carcinoma (n=
182, 7.9 %), endometrioid carcinoma (n=179, 7.7 %), and
adenocarcinoma not otherwise specified (n=108, 4.6 %). Mu-
cinous carcinomas originated in 66.4 % (n=717) from a colo-
rectal carcinoma (CRC). For signet-ring cell carcinomas, the
primary site was most often unknown (n=60, 33.0%), follow-
ed by stomach (n=52, 28.6 %), colon (n=34, 18.8 %), and
appendix (16.5 %). Ductal and lobular carcinomas were re-
sponsible for respectively 7.1 % (n=165) and 6.7 % (n=156)
of all metastases to the ovary (Table 2).
Tumor side
Of all ovarian tumors, 46.3 % was bilateral, 19.8 % was left
sided, and 26.7 % right sided. In 7.2 % of cases, side was
unknown. The primary site of bilateral metastases was the
colon in 26.6 %, breast in 17.7 %, endometrium in 17.1 %,
appendix in 9.0 %, and stomach in 5.7 % of cases while 7.3 %
were from a carcinoma in another organ and 16.6 % of un-
known primary site. Distribution of primary tumor site was
almost the same for metastases to the left and right ovaries as
shown in Fig. 2.
Remarkably, only 40.2 % CRC gave rise to bilateral ovar-
ian metastases, compared to 63.9 % of breast, 62.9 % of gas-
tric, and 58.9 % of appendix carcinomas (Fig. 3).
Side of the primary CRC was related to which ovary was
affected. Metastases to the left ovary originated more often
from carcinomas in the left (descending colon and
rectosigmoid) than from those in the right colon (cecum and
ascending colon) (69.4 %, p<0.0001). The difference was not
statistically significant for metastases to the right ovary. Car-
cinomas of the appendix metastasized more often to the right
ovary (71.6 %, p=0.016). For no other organ was a difference
in side found.
Discussion
Differentiating between a primary ovarian malignancy and a
malignancy metastatic to the ovary is challenging but impor-
tant for prognosis and therapy. Our findings, on the as yet
largest case series of 2312 primary malignancies metastatic
to the ovary, are mostly consistent with earlier smaller studies
with a majority of cases originating from gastrointestinal pri-
maries (Table 3). Differences in distribution are partly associ-
ated with country of origin and partly due to small patient
numbers. Endometrioid carcinomas are a particular problem
as it might be difficult to distinguish between an ovarian me-
tastasis of a primary in the endometrium and a synchronous
primary endometrioid carcinoma in the ovary, as described
earlier. Our dataset includes a relatively low number of uterine
sarcomas and carcinosarcomas (less than 1 % of all cases)
compared to some other studies. It must be noted that in all
studies, the most frequent primary sites were consistently the
gastrointestinal tract, breast, and endometrium [1–8].
The relatively high incidence of metastases from CRC is
remarkable. In the Netherlands, breast cancer is the most com-
mon type of cancer in women (31 %), whereas colorectal
cancer accounts for 13 % [17]. Lung cancer is also fairly
common (9 %) but relatively infrequently metastasizes to the
ovaries. It is unclear why some primary tumor sites are more
likely to metastasize to the ovaries than others.
Spread of appendiceal tumors to the ovaries is a notoriously
complex phenomenon [18], which was also reflected in our
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findings. We found 65 low-grade appendiceal tumors (of
which 62 associated with DPAM) and 104 appendiceal carci-
nomas (of which 24 associated with DPAM). Low-grade
appendiceal tumor metastases in the ovaries were mostly also
low grade, although some presented in the ovary as a carcino-
ma. Conversely, some appendiceal carcinomas manifested as
DPAM, without ovarian involvement by carcinoma. PMCA
was not diagnosed in any case which suggests that peritoneal
involvement might have been underreported. However, exten-
sive discussion of appendiceal tumors is beyond the scope of
this study.
In our series, metastases from an unknown primary site
made up the third largest group, with histological features
suggestive of a primary site in 75 % of cases. Although this
emphasizes the difficulties in distinguishing metastatic from
primarymalignancies, it is reasonable to believe that the actual
number of cases with an unknown primary site is lower. For
some patients, the primary site might have been diagnosed but
considering factors such as age, physical condition, or prog-
nosis, histological evidence might not have been sought. Inci-
dentally, even though median age for several primary sites
such as breast, lung, skin, endometrial, or bladder was signif-
icantly different, the wide range prevents age from being use-
ful as a distinguishing feature.
The most frequently seen histological type of carcinoma
was mucinous, originating from CRC in most cases. Primary
ductal and lobular breast carcinomas were almost equally
prevalent (7.1 and 6.7 % of our cases, respectively), even
though lobular carcinomas account for only 5–15 % of all
breast carcinomas. The loss of expression of the cell-cell
Fig. 2 Side per site of origin
Table 2 Cases subdivided according to histology of ovarian tumor
Histological type Number (%)
Adenocarcinoma 2124 (91.9)
Mucinousa 1167 (50.5)
Serous 76 (3.3)
Endometrioid 179 (7.7)
Clear cell 35 (1.5)
Signet-ring cell 182 (7.9)
Ductal 165 (7.1)
Lobular 156 (6.7)
Otherb 164 (7.1)
Sarcomac 68 (2.9)
Neuro-endocrine carcinoma 61 (2.6)
Squamous cell carcinoma 16 (0.7)
Transitional cell carcinoma 12 (0.5)
Melanoma 10 (0.4)
Unknown 21 (0.9)
Total 2312 (100.0 %)
a Includes 79 DPAM associated lesions
b Includes adenocarcinoma NOS, mixed, adenosquamous, undifferentiated,
hepatoid, tubular, tubulopapillary, and villoglandular adenocarcinomas
c Includes 25 uterine sarcomas and 43 uterine malignant mesodermal
mixed tumors
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adhesion molecule E-cadherin in lobular carcinomas has been
suggested as an explanation for the more frequent spread of
lobular carcinomas to the gynecological and gastrointestinal
tract [19].
Side of the ovarian tumor (left or right) is a poor predictor of
primary site, except for tumors originating from CRC. A left-
sided ovarian tumor was more likely to originate from a left-
sided CRC. Bilateral involvement of the ovaries occurred in half
of the patients and was more common in patients with primary
breast, stomach, and appendix carcinomas, whereas CRC more
frequently presented with unilateral metastasis to the ovary. In-
terestingly, Petru et al. [20] found a significantly better 5-year
survival rate in patients with unilateral compared to bilateral
ovarian involvement. The different patterns of metastasis ac-
cording to primary site, along with differences in survival, sug-
gest that the metastatic routes followed might not be the same.
Chang et al. [21] hypothesized that retrograde lymphatic spread
might be responsible for ovarian metastases from gastrointesti-
nal cancer. Our finding that most CRCs tend to metastasize only
to the ipsilateral ovary suggests that continuous spread through
the peritoneal cavity is involved. How often hematogenous
spread is involved is not clear, although the tendency of breast
cancer to metastasize to both ovaries supports this route. It is
generally accepted that patterns of metastatic spread depend on
Fig. 3 Uni- and bilaterality of
ovarian metastases of most
frequent sites of origin
Table 3 Studies examining frequencies of primary sites in metastases to the ovary
Author Number Large intestine
(%)
Stomach
(%)
Appendix
(%)
Breast
(%)
Endometrium
(%)
Unknown origin
(%)
Other
(%)
Demopoulos 1987 96 12 (13) 6 (6) 1 (1) 32 (33) 14 (15) 0 31 (32)
Petru 1992a 82 23 (28) 22 (27) 0 28 (34) 0 0 9 (11)
Yada-Hashimoto 2003 64 7 (11) 15 (23) 1 (2) 9 (14) 15 (23) 1 (2) 16 (25)
Moore 2004a 59 19 (32) 4 (7) 12 (20) 5 (9) 0 10 (17) 9 (15)
Yemelyanova 2008b 142 46 (32) 5 (4) 26 (18) 0 0 0 65 (46)
De Waal 2009 116 23 (20) 7 (6) 2 (2) 32 (27) 23 (20) 9 (8) 20 (17)
Kondi-Pafiti 2011 97 15 (15) 24 (25) 3 (3) 15 (15) 22 (23) 0 18 (19)
Bruls 2013 2312 767 (33) 103 (5) 169 (7) 330 (14) 395 (17) 382 (17) 166 (7)
a Only non-genital primary tumor sites were included
bOnly mucinous tumors were included
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specific characteristics of tumor cells withmetastatic potential as
well as the micro-environment of recipient tissue [22–24]. Be-
tween organs, properties of the extracellular matrix and vascular
endothelial cells are different in terms of homing ligands and
production of regulatory factors [25, 26]. While it is still not
fully understood why some tumors preferentially metastasize
to particular sites or bilateral rather than unilateral, direct
transperitoneal spread is an important mechanism in our case
series consisting mostly of primary malignancies in the abdo-
men or pelvis.
We only included histologically confirmed cases but did
not revise histology. As for many cases, the criteria used to
conclude that an ovarian malignancy was a metastasis from a
primary elsewhere, were not available, these were not taken
into consideration. While immunohistochemistry is often in-
conclusive, PAX-8 might prove useful as a marker relatively
specific for mucinous ovarian carcinomas [27, 28]. A limita-
tion of our study is its inclusion of patients from a geograph-
ically defined area only and in a specific time frame. However,
comprehensive coverage of the whole Dutch population in the
PALGA database does provide solid evidence of the site of
primary malignancies metastatic to the ovary.
In summary, in our large patient series, colon is the most
frequent primary site of a malignancy metastatic to the ovary,
followed by endometrium and breast. Metastases from breast,
stomach, and appendix carcinomas were mostly bilateral. Co-
lorectal carcinoma metastases were mostly unilateral, with a
trend for the side of CRC to correspond to the side of the
ovarian metastasis. Mechanisms determining patterns of me-
tastasis are still largely unclear, but our observations suggest
that these might be different per primary tumor type.
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